Genentech’s Itovebi demonstrated OS benefit in advanced breast cancer, phase III trial finds – The Cancer Letter

Genentech announced positive topline results from the overall survival analysis of the phase III INAVO120 study investigating Itovebi (inavolisib) in combination with palbociclib (Ibrance) and fulvestrant for people with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. To access this subscriber-only content please log in or subscribe.If […]

Read the full article here

Source: cancerletter.com

Categories: Oncologists1, General Medicine News

Tweets with this article

The Cancer Letter

.@genentech's Itovebi demonstrated OS benefit in advanced breast cancer, phase III trial finds https://t.co/31EQFH0lZH

Gemogenovatucel-T Receives FDA RMAT Designation for Advanced HRP Ovarian Cancer

The FDA granted RMAT designation to gemogenovatucel-T for maintenance treatment after frontline chemotherapy in advanced HRP ovarian cancer.

OncLive.com February 5, 2025

Transforming Cancer Care Through Data: How Texas Colon & Rectal Specialists Enhances Outcomes, Experiences, and Efficiency

How Texas Colon & Rectal Specialists enhance outcomes, experiences, and efficiency data-driven care to improve patient outcome

OncLive.com February 5, 2025

Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence

Arce-Gallego et al. integrate next-generation sequencing with a RAD51 immunofluorescence assay to assess HRR function in advanced prostate cancer. They link RAD51-IF scores to mutations in…

Joaquin Mateo February 5, 2025

Related Articles